Professor of Pediatrics
Director of the Institute for Drug Development
Joint Appointment in Pharmacology and Medicine
Steve obtained his M.D. and Ph.D. at the Medical College of Wisconsin. He is a Pediatric Hematology/Oncologist with about 25 years of experience in cancer drug development. Steve is currently Professor at the Institute for Drug Development at UT Health San Antonio. He was previously Chief Medical Officer, Senior Vice President, and Member of the Executive Committee at ILEX Oncology where he led ILEX’s successful development of clofarabine (Clolar™) and guided that product through a successful ODAC and FDA approval. He also worked on the FDA approval of pralatrexate and romidepsin as well as the post-approval commitments for campath. Steve is inventor on numerous patents and author of over 200 papers, abstracts and chapters in the medical literature. Steve is also a consultant to various biotech and pharmaceutical companies, past Associate Editor of Investigational New Drugs and reviewer for multiple journals including the American Journal of Pediatric Hematology/Oncology, Clinical Cancer Research, Cancer Research and the Journal of Clinical Oncology.
Bonate PL, Cunningham CC, Gaynon P, Jeha S, Kadota R, Lam GN, Razzouk B, Rytting M, Steinherz P, Weitman S, Weitman SD. Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancer. Cancer Chemother Pharmacol 2011 Apr;67(4):875-890.
Mould DR, Baumann A, Kuhlmann J, Keating MJ, Weitman SD, Hillmen P, Brettman LR, Reif S, Bonate PL. Population pharmacokineticspharmacodynamics or aletuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response Br J Clin Pharmacol 2007;64(3):278-291.
Bonate PL, Arthaud L, Cantrell WR, Stephenson K, Secrist JA, Weitman SD. Discovery and development of clofarabine: a nucleoside analogue for treating cancer Nat Rev Drug Discov 2006;5(10):855-863.
Mita AC, Hammond LA, Bonate PL, Weiss G, McCreery H, Syed S, Garrison M, Chu QS, DeBono JS, Jones CB, Weitman SD, Rowinsky EK. Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors Clin Cancer Res 2006;12(17):5207-5215.
Jeha S, Gaynon PS, Razzouk BI, Franklin J, Kadota R, Shen V, Luchtman-Jones L, Rytting M, Bomgaars LR, Rheingold S, Ritchey K, Albano E, Arceci RJ, Goldman S, Griffin T, Altman A, Gordon B, Steinherz L, Weitman SD, Steinherz P. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia J Clin Oncol 2006;24(12):1917-1923.